Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Herz
Erschienen in: Herz 3/2012

01.05.2012 | Main topic

Antithrombotic therapy in patients with acute coronary syndrome and diabetes mellitus

verfasst von: S. Farhan, I. Tentzeris, M.K. Freynhofer, B. Vogel, K. Huber

Erschienen in: Herz | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Acute coronary syndrome (ACS) is associated with high mortality even in the acute phase as well as in the post-acute (chronic) phase. Diabetes mellitus type 2 (DM-2), on the other hand, further increases mortality after ACS. Several new antiplatelet and antithrombotic drugs available for clinical use have also been investigated in patients with DM-2, and the guidelines of the European Society of Cardiology (ESC) were recently adapted. However, in daily clinical practice choosing the most suitable regimen is a challenge in many cases. This review article aims to shed light on and simplify antiplatelet and antithrombotic therapy in ACS patients with DM-2 in order to ease the clinician’s decision-making.
Literatur
1.
Ford ES, Ajani UA, Croft JB et al (2007) Explaining the decrease in U.S. deaths from coronary disease, 1980–2000. N Engl J Med 356:2388–2398PubMedCrossRef
2.
Hardoon SL, Whincup PH, Lennon LT et al (2008) How much of the recent decline in the incidence of myocardial infarction in British men can be explained by changes in cardiovascular risk factors? Evidence from a prospective population-based study. Circulation 117:598–604PubMedCrossRef
3.
Fox CS, Coady S, Sorlie PD et al (2007) Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study. Circulation 115:1544–1550PubMedCrossRef
4.
Stamler J, Vaccaro O, Neaton JD, Wentworth D (1993) Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16:434–444PubMedCrossRef
5.
Brand FN, Abbott RD, Kannel WB (1989) Diabetes, intermittent claudication, and risk of cardiovascular events. The Framingham Study. Diabetes 38:504–509PubMedCrossRef
6.
Haffner SM, Lehto S, Ronnemaa T et al (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229–234PubMedCrossRef
7.
Hunter RW, Hers I (2009) Insulin/IGF-1 hybrid receptor expression on human platelets: consequences for the effect of insulin on platelet function. J Thromb Haemost 7:2123–2130PubMedCrossRef
8.
9.
Kroll MH, Schafer AI (1989) Biochemical mechanisms of platelet activation. Blood 74:1181–1195PubMed
10.
Ferreira IA, Eybrechts KL, Mocking AI et al (2004) IRS-1 mediates inhibition of Ca2 + mobilization by insulin via the inhibitory G-protein Gi. J Biol Chem 279:3254–3264PubMedCrossRef
11.
Ferreira IA, Mocking AI, Feijge MA et al (2006) Platelet inhibition by insulin is absent in type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol 26:417–422PubMedCrossRef
12.
Baldi S, Natali A, Buzzigoli G et al (1996) In vivo effect of insulin on intracellular calcium concentrations: relation to insulin resistance. Metabolism 45:1402–1407PubMedCrossRef
13.
Davi G, Catalano I, Averna M et al (1990) Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med 322:1769–1774PubMedCrossRef
14.
Gawaz M, Ott I, Reininger AJ, Neumann FJ (1994) Effects of magnesium on platelet aggregation and adhesion. Magnesium modulates surface expression of glycoproteins on platelets in vitro and ex vivo. Thromb Haemost 72:912–918PubMed
15.
Schneider DJ, Hardison RM, Lopes N et al (2009) Association between increased platelet P-selectin expression and obesity in patients with type 2 diabetes: a BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) substudy. Diabetes Care 32:944–949PubMedCrossRef
16.
Tschoepe D, Roesen P, Kaufmann L et al (1990) Evidence for abnormal platelet glycoprotein expression in diabetes mellitus. Eur J Clin Invest 20:166–170PubMedCrossRef
17.
Vinik AI, Erbas T, Park TS (2001) Platelet dysfunction in type 2 diabetes. Diabetes Care 24:1476–1485PubMedCrossRef
18.
Belch J, MacCuish A, Campbell I et al (2008) The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 337:a1840PubMedCrossRef
19.
Ogawa H, Nakayama M, Morimoto T et al (2008) Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 300:2134–2141PubMedCrossRef
20.
Colwell JA (2003) Aspirin therapy in diabetes. Diabetes Care 26(Suppl 1):87–88CrossRef
21.
Antithrombotic Trialists’ Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324:71–86CrossRef
22.
Mehta SR, Tanguay JF, Eikelboom JW et al (2010) Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet 376:1233–1243PubMedCrossRef
23.
Mehta SR, Bassand JP, Chrolavicius S et al (2010) Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 363:930–942PubMedCrossRef
24.
Capodanno D, Patel A, Dharmashankar K et al (2011) Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease. Circ Cardiovasc Interv 4:180–187PubMedCrossRef
25.
Hamm CW, Bassand JP, Agewall S et al (2011) ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 32:2999–3054PubMedCrossRef
26.
Balsano F, Rizzon P, Violi F et al (1990) Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. The Studio della Ticlopidina nell’Angina Instabile Group. Circulation 82:17–26PubMedCrossRef
27.
Wijns W, Kolh P, Danchin N et al (2010) Guidelines on myocardial revascularization. Eur Heart J 31:2501–2555PubMedCrossRef
28.
Van de Werf F, Bax J, Betriu A et al (2008) Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the task force on the management of st-segment elevation acute myocardial infarction of the European Society of Cardiology. Eur Heart J 29:2909–2945CrossRef
29.
Steinhubl SR, Berger PB, Mann JT III et al (2002) Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288:2411–2420PubMedCrossRef
30.
Angiolillo DJ, Bernardo E, Ramirez C et al (2006) Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment. J Am Coll Cardiol 48:298–304PubMedCrossRef
31.
Hochholzer W, Trenk D, Fromm MF et al (2010) Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. J Am Coll Cardiol 55:2427–2434PubMedCrossRef
32.
Antman EM, Wiviott SD, Murphy SA et al (2008) Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. J Am Coll Cardiol 51:2028–2033PubMedCrossRef
33.
Murphy SA, Antman EM, Wiviott SD et al (2008) Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. Eur Heart J 29:2473–2479PubMedCrossRef
34.
Wiviott SD, Braunwald E, Angiolillo DJ et al (2008) Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation 118:1626–1636PubMedCrossRef
35.
Montalescot G, Sideris G, Cohen R et al (2010) Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study. Thromb Haemost 103:213–223PubMedCrossRef
36.
Angiolillo DJ, Badimon JJ, Saucedo JF et al (2011) A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial. Eur Heart J 32:838–846PubMedCrossRef
37.
Chin CT, Roe MT, Fox KA et al (2010) Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the Targeted platelet Inhibition to clarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial. Am Heart J 160:16–22 e1PubMedCrossRef
38.
Huber K, Yasothan U, Hamad B, Kirkpatrick P (2009) Prasugrel. Nat Rev Drug Discov 8:449–450PubMedCrossRef
39.
Wallentin L, Becker RC, Budaj A et al (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361:1045–1057PubMedCrossRef
40.
Alber HF, Huber K, Pachinger O, Frick M (2011) Prasugrel vs. ticagrelor in acute coronary syndromes: which one to choose? Wien Klin Wochenschr 123:468–476PubMedCrossRef
41.
Steg PG, James S, Harrington RA et al (2010) Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation 122:2131–2141PubMedCrossRef
42.
Held C, Asenblad N, Bassand JP et al (2011) Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol 57:672–684PubMedCrossRef
43.
James SK, Roe MT, Cannon CP et al (2011) Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. BMJ 342:d3527PubMedCrossRef
44.
James S, Angiolillo DJ, Cornel JH et al (2010) Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J
45.
Summary of product characteristics. http://​www.​ema.​europa.​eu/​docs/​en_​GB/​document_​library/​EPAR_​-_​product_​information/​human/​001241/​WC500100494.​pdf.​ 5 and 11
46.
Biondi-Zoccai G, Lotrionte M et al (2011) Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acute coronary syndromes. Int J Cardiol 150:325–331PubMedCrossRef
47.
Bhatt DL, Lincoff AM, Gibson CM et al (2009) Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 361:2330–2341PubMedCrossRef
48.
Leonardi S, Rao SV, Harrington RA et al (2010) Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI). Am Heart J 160:65–72PubMedCrossRef
49.
Jernberg T, Payne CD, Winters KJ et al (2006) Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 27:1166–173PubMedCrossRef
50.
Wrishko RE, Ernest CS II, Small DS et al (2009) Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38. J Clin Pharmacol 49:984–998PubMedCrossRef
51.
Huber K, Hamad B, Kirkpatrick P (2011) Fresh from the pipeline. Ticagrelor. Nat Rev Drug Discov 10:255–256PubMedCrossRef
52.
Yukhanyan L, Freynhofer MK, Siller-Matula J et al (2011) Genetic variability in response to clopidogrel therapy and its clinical implications. Thromb Haemost 105(Suppl 1):55–59CrossRef
53.
Varenhorst C, James S, Erlinge D et al (2006) Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease. Eur Heart J 30:1744–1752CrossRef
54.
Mega JL, Hochholzer W, Frelinger AL III et al (2011) Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA 306:2221–2228PubMedCrossRef
55.
O’Donoghue ML, Braunwald E, Antman EM et al (2009) Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 374:989–997CrossRef
56.
Gilard M, Arnaud B, Cornily JC et al (2008) Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 51:256–260PubMedCrossRef
57.
Stockl KM, Le L, Zakharyan A, Harada AS et al (2010) Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor. Arch Intern Med 170:704–710PubMedCrossRef
58.
Ho PM, Maddox TM, Wang L et al (2009) Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 301:937–944PubMedCrossRef
59.
Sibbing D, Morath T, Stegherr J et al (2009) Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost 101:714–719PubMed
60.
Siller-Matula JM, Spiel AO, Lang IM et al (2009) Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 157:148 e1–e5PubMedCrossRef
61.
Bhatt DL, Cryer BL, Contant CF et al (2010) Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 363:1909–1917PubMedCrossRef
62.
Siller-Matula JM, Jilma B, Schror K et al (2010) Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis. J Thromb Haemost 8:2624–2641PubMedCrossRef
63.
Tentzeris I, Jarai R, Farhan S et al (2010) Impact of concomitant treatment with proton pump inhibitors and clopidogrel on clinical outcome in patients after coronary stent implantation. Thromb Haemost 104:1211–128PubMedCrossRef
64.
Lau WC, Waskell LA, Watkins PB et al (2003) Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 107:32–37PubMedCrossRef
65.
Neubauer H, Gunesdogan B, Hanefeld C et al (2003) Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function–a flow cytometry study. Eur Heart J 24:1744–1749PubMedCrossRef
66.
Malmstrom RE, Ostergren J, Jorgensen L, Hjemdahl P (2009) Influence of statin treatment on platelet inhibition by clopidogrel – a randomized comparison of rosuvastatin, atorvastatin and simvastatin co-treatment. J Intern Med 266:457–466PubMedCrossRef
67.
Sibbing D, Beckerath N von, Morath T et al (2010) Oral anticoagulation with coumarin derivatives and antiplatelet effects of clopidogrel. Eur Heart J 31:1205–1211PubMedCrossRef
68.
Harmsze AM, Robijns K, Werkum JW van et al (2010) The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response. Thromb Haemost 103:920–925PubMedCrossRef
69.
Natarajan A, Zaman AG, Marshall SM (2008) Platelet hyperactivity in type 2 diabetes: role of antiplatelet agents. Diab Vasc Dis Res 5:138–144PubMedCrossRef
70.
Roffi M, Chew DP, Mukherjee D et al (2001) Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation 104:2767–2771PubMedCrossRef
71.
Marso SP, Lincoff AM, Ellis SG et al (1999) Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy. Circulation 100:2477–2484PubMed
72.
Mehilli J, Kastrati A, Schuhlen H et al (2004) Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Circulation 110:3627–3635PubMedCrossRef
73.
Ndrepepa G, Kastrati A, Mehilli J et al (2008) One-year clinical outcomes with abciximab vs. placebo in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention after pre-treatment with clopidogrel: results of the ISAR-REACT 2 randomized trial. Eur Heart J 29:455–461PubMedCrossRef
74.
Boden G, Vaidyula VR, Homko C et al (2007) Circulating tissue factor procoagulant activity and thrombin generation in patients with type 2 diabetes: effects of insulin and glucose. J Clin Endocrinol Metab 92:4352–4358PubMedCrossRef
75.
Ceriello A, Giugliano D, Quatraro A et al (1988) Blood glucose may condition factor VII levels in diabetic and normal subjects. Diabetologia 31:889–891PubMedCrossRef
76.
Stegenga ME, Crabben SN van der, Levi M et al (2006) Hyperglycemia stimulates coagulation, whereas hyperinsulinemia impairs fibrinolysis in healthy humans. Diabetes 55:1807–1812PubMedCrossRef
77.
Stegenga ME, Crabben SN van der, Blumer RM et al (2008) Hyperglycemia enhances coagulation and reduces neutrophil degranulation, whereas hyperinsulinemia inhibits fibrinolysis during human endotoxemia. Blood 112:82–89PubMedCrossRef
78.
Seljeflot I, Larsen JR, Dahl-Jorgensen K et al (2006) Fibrinolytic activity is highly influenced by long-term glycemic control in Type 1 diabetic patients. J Thromb Haemost 4:686–688PubMedCrossRef
79.
Haffner S, Temprosa M, Crandall J et al (2005) Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes 54:1566–1572PubMedCrossRef
80.
Gerstein HC, Miller ME, Byington RP et al (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545–2559PubMedCrossRef
81.
Duckworth W, Abraira C, Moritz T et al (2009) Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360:129–139PubMedCrossRef
82.
Antman EM, McCabe CH, Gurfinkel EP et al (1999) Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 100:1593–1601PubMed
83.
Cohen M, Demers C, Gurfinkel EP et al (1997) A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and safety of subcutaneous enoxaparin in non-q-wave coronary events study group. N Engl J Med 337:447–452PubMedCrossRef
84.
Ferguson JJ, Califf RM, Antman EM et al (2004) Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 292:45–54PubMedCrossRef
85.
Petersen JL, Mahaffey KW, Hasselblad V et al (2004) Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview. JAMA 292:89–96PubMedCrossRef
86.
Mahaffey KW, Cohen M, Garg J et al (2005) High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin: outcomes at 6 months and 1 year in the SYNERGY trial. JAMA 294:2594–2600PubMedCrossRef
87.
Baird SH, Menown IB, McBride SJ et al (2002) Randomized comparison of enoxaparin with unfractionated heparin following fibrinolytic therapy for acute myocardial infarction. Eur Heart J 23:627–632PubMedCrossRef
88.
Ross AM, Molhoek P, Lundergan C et al (2001) Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of Heparin and Aspirin Reperfusion Therapy (HART II). Circulation 104:648–652PubMedCrossRef
89.
Wallentin L, Goldstein P, Armstrong PW et al (2003) Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. Circulation 108:135–142PubMedCrossRef
90.
Eikelboom JW, Quinlan DJ, Mehta SR et al (2005) Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction: a meta-analysis of the randomized trials. Circulation 112:3855–3867PubMedCrossRef
91.
Antman EM, Morrow DA, McCabe CH et al (2005) Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction. Design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25). Am Heart J 149:217–226PubMedCrossRef
92.
Antman EM, Morrow DA, McCabe CH et al (2006) Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med 354:1477–1488PubMedCrossRef
93.
Morrow DA, Antman EM, Murphy SA et al (2007) Effect of enoxaparin versus unfractionated heparin in diabetic patients with ST-elevation myocardial infarction in the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25) trial. Am Heart J 154:1078–1084, 84 e1PubMedCrossRef
94.
Zeymer U, Gitt A, Zahn R et al (2009) Efficacy and safety of enoxaparin in combination with and without GP IIb/IIIa inhibitors in unselected patients with ST segment elevation myocardial infarction treated with primary percutaneous coronary intervention. EuroIntervention 4:524–528PubMedCrossRef
95.
Montalescot G, Zeymer U, Silvain J et al (2011) Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial. Lancet 378:693–703PubMedCrossRef
96.
Sculpher MJ, Lozano-Ortega G, Sambrook J et al (2009) Fondaparinux versus Enoxaparin in non-ST-elevation acute coronary syndromes: short-term cost and long-term cost-effectiveness using data from the fifth organization to assess strategies in acute ischemic syndromes investigators (OASIS-5) trial. Am Heart J 157:845–852PubMedCrossRef
97.
Peters R, SR M (2007) Mortality benefit of fondaparinux versus enoxaparin in diabetic patients with non-ST elevation acute coronary syndrome (NSTE-ACS): A Subanalysis of OASIS-5. J Thromb Haemost 5:P-M-683
98.
Yusuf S, Mehta SR, Chrolavicius S et al (2006) Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 295:1519–1530PubMedCrossRef
99.
Oldgren J, Wallentin L, Afzal R et al (2008) Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment. Eur Heart J 29:315–323PubMedCrossRef
100.
Peters RJ, Joyner C, Bassand JP et al (2008) The role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: a subgroup analysis of the OASIS-6 trial. Eur Heart J 29:324–331PubMedCrossRef
101.
Brieger DB, Mak KH, Kottke-Marchant K, Topol EJ (1998) Heparin-induced thrombocytopenia. J Am Coll Cardiol 31:1449–1459PubMedCrossRef
102.
White HD, Chew DP, Hoekstra JW et al (2008) Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-ST-segment elevation acute coronary syndromes managed with an invasive strategy: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. J Am Coll Cardiol 51:1734–1741PubMedCrossRef
103.
Mehran R, Lansky AJ, Witzenbichler B et al (2009) Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet 51:1149–1159CrossRef
104.
Rajagopal V, Lincoff AM, Cohen DJ et al (2006) Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: an analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial. Am Heart J 152:149–154PubMedCrossRef
105.
Kastrati A, Neumann FJ, Schulz S et al (2011) Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction. N Engl J Med 365:1980–1989PubMedCrossRef
106.
White HD, Ohman EM, Lincoff AM et al (2008) Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. J Am Coll Cardiol 52:807–814PubMedCrossRef
107.
Gurm HS, Lincoff AM, Lee D et al (2004) Outcome of acute ST-segment elevation myocardial infarction in diabetics treated with fibrinolytic or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: lessons from the GUSTO V trial. J Am Coll Cardiol 43:542–548PubMedCrossRef
108.
Feit F, Manoukian SV, Ebrahimi R et al (2008) Safety and efficacy of bivalirudin monotherapy in patients with diabetes mellitus and acute coronary syndromes: a report from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. J Am Coll Cardiol 51:1645–1652PubMedCrossRef
109.
Witzenbichler B, Mehran R, Guagliumi G et al (2011) Impact of diabetes mellitus on the safety and effectiveness of bivalirudin in patients with acute myocardial infarction undergoing primary angioplasty: analysis from the HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction) trial. JACC Cardiovasc Interv 4:760–768PubMedCrossRef
110.
Aoki J, Lansky AJ, Mehran R et al (2009) Early stent thrombosis in patients with acute coronary syndromes treated with drug-eluting and bare metal stents: the acute catheterization and urgent intervention triage strategy trial. Circulation 119:687–698PubMedCrossRef
111.
Dangas GD, lansky AJ, Brodie BR (2009) Predictors of stent thrombosis after primary angioplasty in acute myocardial infarction: The HORIZONS-AMI Trial. ACC Annual Scientific session
112.
Coughlin SR (2003) Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost 3:1800–1814CrossRef
113.
Tricoci P, Huang Z, Held C et al (2012) Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 366:20–30PubMedCrossRef
114.
Goto S, Ogawa H, Takeuchi M et al (2010) Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease. Eur Heart J 31:2601–2613PubMedCrossRef
115.
Mega JL, Braunwald E, Mohanavelu S et al (2009) Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 374:29–38PubMedCrossRef
116.
Gibson CM, Mega JL, Burton P et al (2011) Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome. Am Heart J 161:815–21 e6PubMedCrossRef
117.
Alexander JH, Becker RC, Bhatt DL et al (2009) Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation 119:2877–2885PubMedCrossRef
118.
Alexander JH, Lopes RD, James S et al (2011) Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 365:699–708PubMedCrossRef
119.
Steg PG, Mehta SR, Jukema JW et al (2011) RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. Eur Heart J 32:2541–2554PubMedCrossRef
120.
Sabatine MS, Antman EM, Widimsky P et al (2009) Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial. Lancet 374:787–795PubMedCrossRef
121.
Oldgren J, Budaj A, Granger CB et al (2011) Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J 32:2781–2789PubMedCrossRef
122.
Angiolillo DJ, Capranzano P, Goto S et al (2008) A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. Eur Heart J 29:2202–2211PubMedCrossRef
123.
Lee SW, Park SW, Kim YH et al (2008) Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Diabetic Patients). J Am Coll Cardiol 51:1181–1187PubMedCrossRef
124.
125.
Lee SW, Chun KJ, Park SW et al (2008) Comparison of Triple antiplatelet therapy and dual antiplatelet therapy in patients at high risk of restenosis after drug-eluting stent implantation (from the DECLARE-DIABETES and -LONG Trials). Am J Cardiol 105:168–173CrossRef
Metadaten
Titel
Antithrombotic therapy in patients with acute coronary syndrome and diabetes mellitus
verfasst von
S. Farhan
I. Tentzeris
M.K. Freynhofer
B. Vogel
K. Huber
Publikationsdatum
01.05.2012
Verlag
Urban and Vogel
Erschienen in
Herz / Ausgabe 3/2012
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI
https://doi.org/10.1007/s00059-012-3610-4

Weitere Artikel der Ausgabe 3/2012

Herz 3/2012 Zur Ausgabe

Image of the month

Visualization of dual coronary artery fistulae drainage to the right ventricle by transthoracic echocardiography

Schwerpunkt

Kardiovaskuläre Effekte inkretinbasierter Therapien

Originalarbeit

Reduktion der stationären Verweildauer bei Patienten mit akutem Koronarsyndrom durch Einrichtung einer Chest Pain Unit

Main topic

Atrial fibrillation and diabetes mellitus

Main topic

Komorbidität, Hypoglykämie und geeignete Auswahl der antidiabetischen Pharmakotherapie bei Diabetikern mit Herzinsuffizienz in der klinischen Praxis in Deutschland

Case study

Complex coronary artery anatomy in a patient with prolapsing left atrial myxoma

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen